Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DenosuRel
- Development stage
- Unknown
- Lead developer
- Reliance Life Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
DenosuRel is a biosimilar of denosumab, developed and manufactured by Reliance Life Sciences. It is a human IgG2 monoclonal antibody that targets and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), a protein essential for the formation, function, and survival of osteoclasts. By blocking the interaction between RANKL and its receptor RANK on the surface of osteoclasts and their precursors, DenosuRel reduces bone resorption and increases bone mineral density. The drug is administered subcutaneously and is available in different strengths, including a 120mg dose (marketed as DenosuRel) and a 60mg dose (marketed as DenOsteoRel). It is indicated for the treatment of postmenopausal osteoporosis, bone loss due to hormonal therapy or steroids, and the prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma.
- Brand names
- DenosuRelDenOsteoRel
- Other names
- denosumab biosimilar
02
Targets
RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)
Beyond the preview
Go deeper on DenosuRel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DenosuRel.